Search results

Jump to navigation Jump to search
View (previous 20 | ) (20 | 50 | 100 | 250 | 500)
  • substance or treatment of no therapeutic value
    6 statements, 0 sitelinks - 08:42, 26 November 2023
  • for a medical treatment, an effect that is attributable to an expectation that the regimen will have an effect
    3 statements, 0 sitelinks - 08:42, 26 November 2023
  • * [[Meds (album)|''Meds'' (album)]], by the rock band Placebo ...
    327 bytes (47 words) - 22:32, 8 January 2023
  • ...besides metformin). Patients received either 50&nbsp;mg ipragliflozin or a placebo. The drugs were identical in all physical forms. The patients were prohibit ...emoglobin A<sub>1c</sub>]] were −0.94% and −0.47% in the ipragliflozin and placebo groups, respectively (between-group difference −0.46%, [[p-value|''p'']] <0 ...
    7 KB (1,058 words) - 21:01, 20 February 2024
  • ...besides metformin). Patients received either 50&nbsp;mg ipragliflozin or a placebo. The drugs were identical in all physical forms. The patients were prohibit ...emoglobin A<sub>1c</sub>]] were −0.94% and −0.47% in the ipragliflozin and placebo groups, respectively (between-group difference −0.46%, [[p-value|''p'']] <0 ...
    7 KB (1,098 words) - 21:00, 20 February 2024
  • ...nificant]] difference exists in the occurrence of [[hypoglycemia]] between placebo and sitagliptin. In those taking [[sulphonylurea]]s, the risk of [[hypoglyc ...liptin has been shown to lower [[HbA1c]] level by about 0.7% points versus placebo. It is slightly less effective than metformin when used as a [[monotherapy] ...
    8 KB (1,202 words) - 20:17, 12 March 2024
  • ...nificant]] difference exists in the occurrence of [[hypoglycemia]] between placebo and sitagliptin. In those taking [[sulphonylurea]]s, the risk of [[hypoglyc ...liptin has been shown to lower [[HbA1c]] level by about 0.7% points versus placebo. It is slightly less effective than metformin when used as a [[monotherapy] ...
    9 KB (1,250 words) - 20:17, 12 March 2024
  • ...民間療法で使用されていた植物[[phytochemical/ja|植物化学物質]]に基づいているものもある。研究者らは、代替療法の多くは「統計的に[[placebo/ja|偽薬]]治療と区別できない」と述べている。 ...ば、持っていない場合もある。多くは単に[[:en:tradition|伝統]]や[[:en:habituation|習慣]]の結果として、あるいは[[placebo effect/ja|プラセボ効果]]を誘発するのに有効であるために使用されている。 ...
    23 KB (786 words) - 22:26, 17 March 2024
  • ...f it results in weight loss that is statistically significant greater than placebo and generally at least five percent of body weight over six months that com !placebo-adjusted percent bodyweight lost (highest dose studied) ...
    17 KB (2,406 words) - 18:16, 7 March 2024
  • ...f it results in weight loss that is statistically significant greater than placebo and generally at least five percent of body weight over six months that com !placebo-adjusted percent bodyweight lost (highest dose studied) ...
    18 KB (2,460 words) - 18:15, 7 March 2024
  • ...patients shows improvement in the control of glucose, when compared with [[placebo|placebos]], [[metformin]], [[sulfonylurea]], [[thiazolidinediones]], insuli ..., summed up, were that 10&nbsp;mg of dapagliflozin showed more effect than placebo in the control of glucose, when given for 24 weeks. However, no inferior ef ...
    17 KB (2,477 words) - 09:56, 14 February 2024
  • ...patients shows improvement in the control of glucose, when compared with [[placebo|placebos]], [[metformin]], [[sulfonylurea]], [[thiazolidinediones]], insuli ..., summed up, were that 10&nbsp;mg of dapagliflozin showed more effect than placebo in the control of glucose, when given for 24 weeks. However, no inferior ef ...
    17 KB (2,553 words) - 09:56, 14 February 2024
  • ...ration sulfonylureas relative to metformin (RR 1.0), insulin (RR 1.0), or placebo. The FDA requires sulfonylureas to carry a label warning regarding increase ...
    12 KB (1,572 words) - 20:36, 12 March 2024
  • ...uck氏は、2型糖尿病患者の血糖コントロールにおけるSGLT-2阻害薬の活性に関する研究の[[Meta-analysis/ja|メタ解析]]では、[[placebo/ja|プラセボ]]、[[metformin/ja|メトホルミン]]、[[sulfonylurea/ja|スルホニルウレア]]、[[thiazolidi ...
    21 KB (632 words) - 15:58, 14 February 2024
  • ...ration sulfonylureas relative to metformin (RR 1.0), insulin (RR 1.0), or placebo. The FDA requires sulfonylureas to carry a label warning regarding increase ...
    12 KB (1,638 words) - 20:35, 12 March 2024
  • ...d with a 58% increased risk of developing acute pancreatitis compared with placebo or no treatment. ...
    6 KB (770 words) - 17:34, 12 March 2024
  • シタグリプチンによる副作用は、まれに[[nausea/ja|吐き気]]、[[common cold/ja|感冒]]様症状、光線過敏症を除き、[[placebo/ja|プラセボ]]と同様である。シタグリプチンは下痢のリスクを増加させない。[[hypoglycemia/ja|低血糖]]の発現には、プラセボとシタグ ...
    10 KB (637 words) - 22:17, 12 March 2024
  • ...d with a 58% increased risk of developing acute pancreatitis compared with placebo or no treatment. ...
    6 KB (812 words) - 17:34, 12 March 2024
  • ...alternative treatments are "statistically indistinguishable from [[Placebo|placebo treatments]]". ...] or [[Habituation|habit]] or because they are effective in inducing the [[placebo effect]]. ...
    18 KB (2,575 words) - 16:03, 17 March 2024
  • ...reduce heart attack, stroke, and cardiovascular death by 25% relative to a placebo in those with statin-resistant hypertriglyceridemia. ...en either 600&nbsp;mg/day DHA alone, 600 or 1800&nbsp;mg/day EPA alone, or placebo for six weeks. The DHA group showed a significant 20% drop in triglycerides ...
    12 KB (1,765 words) - 20:40, 14 April 2024
View (previous 20 | ) (20 | 50 | 100 | 250 | 500)